Exploring anti-TB leads from natural products library originated from marine microbes and medicinal plants

Antonie Van Leeuwenhoek. 2012 Oct;102(3):447-61. doi: 10.1007/s10482-012-9777-0. Epub 2012 Jul 20.

Abstract

Multidrug-resistant tuberculosis (MDR-TB) and TB-HIV co-infection have become a great threat to global health. However, the last truly novel drug that was approved for the treatment of TB was discovered 40 years ago. The search for new effective drugs against TB has never been more intensive. Natural products derived from microbes and medicinal plants have been an important source of TB therapeutics. Recent advances have been made to accelerate the discovery rate of novel TB drugs including diversifying strategies for environmental strains, high-throughput screening (HTS) assays, and chemical diversity. This review will discuss the challenges of finding novel natural products with anti-TB activity from marine microbes and plant medicines, including biodiversity- and taxonomy-guided microbial natural products library construction, target- and cell-based HTS, and bioassay-directed isolation of anti-TB substances from traditional medicines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antitubercular Agents / isolation & purification
  • Antitubercular Agents / pharmacology*
  • Aquatic Organisms / chemistry*
  • Biological Products / isolation & purification
  • Biological Products / pharmacology*
  • Drug Evaluation, Preclinical
  • High-Throughput Screening Assays
  • Humans
  • Plants, Medicinal / chemistry*
  • Seawater / microbiology*

Substances

  • Antitubercular Agents
  • Biological Products